Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer.

Autor: Sharma A; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India., Dubey R; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India., Asati V; Department of Medical Oncology, Sri Aurobindo Medical College and PG Institute, Indore, MP, India., Baweja GS; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India., Gupta S; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India., Asati V; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India. vivekasatipharma47@gmail.com.
Jazyk: angličtina
Zdroj: Molecular diversity [Mol Divers] 2024 Apr 20. Date of Electronic Publication: 2024 Apr 20.
DOI: 10.1007/s11030-023-10795-4
Abstrakt: One of the most perilous illnesses in the world is cancer. The cancer may be associated with the mutation of different genes inside the body. The PIM kinase, also known as the serine/threonine kinase, plays a critical role in the biology of different kinds of cancer. They are widely distributed and associated with several biological processes, including cell division, proliferation, and death. Aberration of PIM-1 kinase is found in varieties of cancer. Prostate cancer and leukemia can both be effectively treated with PIM-1 kinase inhibitors. There are several potent compounds that have been explored in this review based on heterocyclic compounds for the treatment of prostate cancer and leukemia that have strong effects on the suppression of PIM-1 kinase. The present review summarizes the PIM-1 kinase pathway, their inhibitors under clinical trial, related patents, and SAR studies of several monocyclic, bicyclic, and polycyclic compounds. The study related to their molecular interactions with receptors is also included in the present manuscript. The study may be beneficial to scientists for the development of novel compounds as PIM-1 inhibitors in the treatment of prostate cancer and leukemia.
(© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: